

Literaturübersicht: Medizinalcannabis bei Fibromyalgie

Stand: 04.11.2021, SGCM-SSCM

Berger AA, Keefe J, Winnick A, Gilbert E, Eskander JP, Yazdi C, et al. Cannabis and cannabidiol (CBD) for the treatment of fibromyalgia. *Recent Adv Chronic Pain* Volume. 2020;34:617–31.

Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, et al. Opposite Effects of Δ -9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology. *Neuropsychopharmacology*. 2010;35:764–74.

Cameron EC, Hemingway SL. Cannabinoids for fibromyalgia pain: a critical review of recent studies (2015-2019). *J Cannabis Res. BioMed Central*; 2020;2:19–19.

Canadian Government – Health Canada. Information for Healthcare Professionals – Cannabis and the Cannabinoids 10.2018 [Internet]. Available from: <https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis>

Chaves C, Bittencourt PCT, Pelegrini A. Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. *Pain Med*. 2020;21:2212–8.

Cooper ZD, Craft RM. Sex-Dependent Effects of Cannabis and Cannabinoids: A Translational Perspective. *Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol*. 2018;43:34–51.

Ehrenkranz J, Levine MA. Bones and Joints: The Effects of Cannabinoids on the Skeleton. *J Clin Endocrinol Metab*. 2019;104:4683–94.

Fiz J, Durán M, Capellà D, Carbonell J, Farré M. Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life. *PLoS One*. 2011;6:e18440.

Fitzcharles M-A, Baerwald C, Ablin J, Häuser W. Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): A systematic review of randomized controlled trials. *Schmerz Berl Ger*. 2016;30:47–61.

Foster BC, Abramovici H, Harris CS. Cannabis and Cannabinoids: Kinetics and Interactions. *Am J Med*. 2019;132:1266–70.

Gaston T, Bebin E, Cutter G, Liu Y, Szaflarski J, UAB CBD Program. Interactions between cannabidiol and commonly used antiepileptic drugs. *Epilepsia*. 2017;58:1586–92.

Gerardi MC, Batticciotto A, Talotta R, Ditto MC, Atzeni F, Sarzi-Puttini P. Efficacy of Cannabis Flos in Patients with Fibromyalgia: A Monocentric Observational Study [abstract]. *Arthritis Rheumatol*. 2016;68 (suppl 10).

Giorgi V, Bongiovanni S, Atzeni F, Marotto D, Salaffi F, Sarzi-Puttini P. Adding medical cannabis to standard analgesic treatment for fibromyalgia: a prospective observational study. *Clin Exp Rheumatol*. 2020;38 Suppl 123:53–9.

Grayson L, Vines B, Nichol K, Szaflarski JP, UAB CBD Program. An interaction between warfarin and cannabidiol, a case report. *Epilepsy Behav Case Rep*. 2017;9:10–1.

Habib G, Khazin F, Artul S. The Effect of Medical Cannabis on Pain Level and Quality of Sleep among Rheumatology Clinic Outpatients. *Pain Res Manag. Hindawi*; 2021;2021:1756588–1756588.

Habib G, Artul S. Medical Cannabis for the Treatment of Fibromyalgia. *J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis*. 2018;24:255–8.

Habib G, Avisar I. The Consumption of Cannabis by Fibromyalgia Patients in Israel. *Pain Res Treat*. 2018;2018:7829427.

Hudson R, Renard J, Norris C, Rushlow WJ, Laviolette SR. Cannabidiol Counteracts the Psychotropic Side-Effects of Δ -9-Tetrahydrocannabinol in the Ventral Hippocampus through Bidirectional Control of ERK1-2 Phosphorylation. *J Neurosci Off J Soc Neurosci*. 2019;39:8762–77.

- Kuhathasan N, Dufort A, MacKillop J, Gottschalk R, Minuzzi L, Frey BN. The use of cannabinoids for sleep: A critical review on clinical trials. *Exp Clin Psychopharmacol*. 2019;27:383–401.
- Qian Y, Gurley BJ, Markowitz JS. The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications. *J Clin Psychopharmacol*. 2019;39:462–71.
- Sagy I, Bar-Lev Schleider L, Abu-Shakra M, Novack V. Safety and Efficacy of Medical Cannabis in Fibromyalgia. *J Clin Med*. 2019;8.
- Sarzi-Puttini P, Ablin J, Trabelsi A, Fitzcharles M-A, Marotto D, Häuser W. Cannabinoids in the treatment of rheumatic diseases: Pros and cons. *Autoimmun Rev*. 2019;18:102409.
- Sarzi-Puttini P, Batticciotto A, Atzeni F, Bazzichi L, Di Franco M, Salaffi F, et al. Medical cannabis and cannabinoids in rheumatology: where are we now? *Expert Rev Clin Immunol*. 2019;15:1019–32.
- Schley M, Legler A, Skopp G, Schmelz M, Konrad C, Rukwied R. Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief. *Curr Med Res Opin*. 2006;22:1269–76.
- Ste-Marie PA, Fitzcharles M-A, Gamsa A, Ware MA, Shir Y. Association of herbal cannabis use with negative psychosocial parameters in patients with fibromyalgia. *Arthritis Care Res*. 2012;64:1202–8.
- van de Donk T, Niesters M, Kowal MA, Olofsen E, Dahan A, van Velzen M. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. *Pain*. 2019;160:860–9.
- Walitt B, Klose P, Fitzcharles M-A, Phillips T, Häuser W. Cannabinoids for fibromyalgia. *Cochrane Database Syst Rev*. 2016;7:CD011694.
- Weber J, Schley M, Casutt M, Gerber H, Schuepfer G, Rukwied R, et al. Tetrahydrocannabinol (Delta 9-THC) Treatment in Chronic Central Neuropathic Pain and Fibromyalgia Patients: Results of a Multicenter Survey. *Anesthesiol Res Pract*. 2009;2009.
- Yassin M, Oron A, Robinson D. Effect of adding medical cannabis to analgesic treatment in patients with low back pain related to fibromyalgia: an observational cross-over single centre study. *Clin Exp Rheumatol*. 2019;37 Suppl 116:13–20.